secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-07-03T23:59:59+00:00
Accession:  0001104659-23-077598
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics CAO departs; appoints Eliot Lurier as Interim CFO
---------------------------------------------------------------------

- Michael Loiacono, Chief Accounting Officer, separated effective June 30, 2023.
- Company agreed to provide severance benefits consistent with employment agreement upon execution of release.
- Eliot M. Lurier appointed Interim CFO effective June 30; serves via Danforth Advisors consulting agreement.
- Mr. Lurier, age 65, has served as consultant to life science companies through Danforth since July 2021.
- No family relationships or material transactions between Lurier and company officers/directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923077598/0001104659-23-077598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923077598/tm2319618d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-077598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer